chufangao/CTO huggingface dataset:
Clinical trial NCT03808935: Cannabis Extract in Refractory Epilepsy Study
Official title: A Double-Blind, Placebo-Controlled, Parallel-Group Study of Cannabidiol Plus Tetrahydrocannabinol (CBD+THC) Given as Adjunctive Therapy in Patients With Refractory Seizures
Acronym: CERES
Sponsor: The Epilepsy Research Program of the Ontario Brain Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Participants are no longer being examined or receiving intervention.
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-10
Primary completion date: 2020-03-15
Completion date: 2020-03-15
Clinical trial NCT03152786: Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Official title: Evaluating the Effect of ADRB2 Blockers on PKA/BAD/CREB Signaling in Patients Undergoing Prostatectomy
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: PIs not interested in continuing with the trial.
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-15
Primary completion date: 2021-06-15
Completion date: 2023-02-28
Clinical trial NCT03362515: Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide
Official title: Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide
Sponsor: Thomas Jefferson University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated prematurely due to low enrollment numbers and the development of better drugs to treat polyps (ie. Biologics) which were not available when the study began.
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-01
Primary completion date: 2022-04-14
Completion date: 2022-04-14
Plan to share individual participant data: NO
Clinical trial NCT00508274: Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
Official title: An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.
Enrollment: 52.0 (ACTUAL)
Number of arms: 1.0
Start date: 2007-07-18
Primary completion date: 2015-12-02
Completion date: 2020-07-01
Limitations and caveats: Data collection post 1-Jul-2019 was not reportable due to local regulations in China.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02658916: Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
Official title: A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: 251PP301(NCT03068468) primary endpoint was not met;further development of Gosuranemab BIIB092 in progressive supranuclear palsy will not be pursued.
Enrollment: 47.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-02-22
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Clinical trial NCT04582669: Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
Official title: Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: This study was administratively closed.
Enrollment: 11.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-01-24
Primary completion date: 2022-10-12
Completion date: 2022-10-12
Clinical trial NCT03670069: Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Official title: A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune Microenvironment
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was multifactorial, including slow enrollment in the last remaining cohort and a lack of evidence of clinical benefit.
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-30
Primary completion date: 2023-03-04
Completion date: 2024-05-06
Plan to share individual participant data: NO
Clinical trial NCT04992273: COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
Official title: A Phase 2A, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous Anti- Spike(s) SARS-COV-2 Monoclonal Antibodies (Casirivimab and Imdevimab) in High-Risk Pediatric Subjects Under 12 Years of Age
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Emerging SARS-CoV-2 variants impacting susceptibility to study drug
Enrollment: 7.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-09-13
Primary completion date: 2022-06-01
Completion date: 2022-06-01
Limitations and caveats: The study was terminated early due to emerging SARS-CoV-2 variants impacting susceptibility to the study drug. The early termination was not due to safety findings.
Plan to share individual participant data: YES
IPD sharing description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
IPD access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Clinical trial NCT00304070: Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
Official title: Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study
Sponsor: Children's Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 78.0 (ACTUAL)
Number of arms: 3.0
Start date: 2007-05-03
Primary completion date: 2015-12-31
Completion date: 2023-06-30
Plan to share individual participant data: YES
IPD sharing description: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive
Clinical trial NCT04109950: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
Official title: An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study terminated early, main goals achieved
Enrollment: 452.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-04
Primary completion date: 2023-11-09
Completion date: 2023-11-09
Plan to share individual participant data: YES
IPD sharing description: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Clinical trial NCT04840784: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
Official title: A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AML
Sponsor: Shengke Pharmaceuticals (Jiangsu) Limited, China (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The reasons for early termination is due to slow recruitment
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-29
Primary completion date: 2023-05-02
Completion date: 2023-05-02
Plan to share individual participant data: NO
Clinical trial NCT05976334: An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
Official title: A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]Subasumstat in Patients With Advanced or Metastatic Solid Tumors
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-11-14
Primary completion date: 2024-06-21
Completion date: 2024-07-16
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT03194646: Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
Official title: An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Versus Standard of Care
Acronym: ASTEROID 6
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to a change in the development program, the study was closed prematurely.
Enrollment: 1272.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-06-30
Primary completion date: 2019-05-10
Completion date: 2024-07-11
Baseline population: Participants in Full analysis set (FAS) was analyzed. The FAS consisted of all randomized subjects, excluding randomized subjects who did not start treatment Period 1 (never received study drug) due to the study being temporarily paused, including 1264 participants.
Limitations and caveats: Only two patients are in safety follow up due to local requirement.
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Clinical trial NCT02635386: EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
Official title: Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women
Sponsor: Woman's (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 119.0 (ACTUAL)
Number of arms: 5.0
Start date: 2016-03-22
Primary completion date: 2020-07-22
Completion date: 2020-10-09
Baseline population: All participants were started on medicine
Limitations and caveats: One limitation of this study is the lack of a placebo only arm. As we were interested in the effects of different treatment regimens for obese women with PCOS, this study was designed to provide all patients with drug therapy. Limitations of the present study further include the absence of gold-standard measures of insulin sensitivity ; instead we used the OGTT using established surrogate measures.. Last, serial assessments were over only 24 weeks of treatment.
Plan to share individual participant data: NO
IPD sharing description: Individual data will only be shared with participant
Clinical trial NCT04706793: Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)
Official title: A Phase 3, Double-Blind, Placebo-Controlled, 40-Week Extension Study to Assess the Efficacy and Safety of Etrasimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-25
Primary completion date: 2022-08-03
Completion date: 2022-08-03
Baseline population: Full Analysis Set: All randomized participants who received at least 1 dose of study intervention.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03014804: Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Official title: A Phase II Clinical Trial Evaluating Combination Therapy Using DCVax-L (Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen) and Nivolumab (an Anti-PD-1 Antibody) for Subjects With Recurrent Glioblastoma Multiforme
Sponsor: Jonsson Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Final contract negotiations
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-01
Primary completion date: 2020-12-01
Completion date: 2022-12-01
Clinical trial NCT05491447: A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
Official title: A Phase 2 Clinical Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 Ointment in Adult Subjects With Atopic Dermatitis
Sponsor: BioMimetix JV, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funding constraints
Enrollment: 103.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-01-08
Primary completion date: 2023-12-30
Completion date: 2024-04-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03634839: Effects of E-cigarette Flavors on Youth TCORS 2.0
Official title: Effects of E-cigarette Flavors on Youth
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-07
Primary completion date: 2023-06-16
Completion date: 2023-07-20
Clinical trial NCT05309512: Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors
Official title: A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of KN052 in Chinese Subjects With Advanced Solid Tumors
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Based on the differentiated R\&D strategy, the sponsor applies for the termination of the project.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-05-27
Primary completion date: 2023-11-14
Completion date: 2023-11-14
Plan to share individual participant data: NO
Clinical trial NCT04105062: LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Official title: Evaluation of LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: One of the investigators is leaving the University.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-12-31
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT03746522: Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Official title: A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
Sponsor: Rhythm Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-23
Primary completion date: 2020-11-16
Completion date: 2021-03-08
Baseline population: Safety Analysis Set defined as participants who received at least 1 dose of study drug (placebo or setmelanotide).
Plan to share individual participant data: NO
Clinical trial NCT03235869: Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
Official title: A Single Arm Pilot Study of Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: The company pulled durvalumab from heme malignancies
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-01
Primary completion date: 2023-03-01
Completion date: 2023-03-01
Clinical trial NCT04142242: Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
Official title: Safety and Immunogenicity of a Single Dose of MenACYW Conjugate Vaccine at Least 3 Years Following Initial Vaccination With Either Menomune® Vaccine or MenACYW Conjugate Vaccine in Older Adults
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 471.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-10-04
Primary completion date: 2020-04-01
Completion date: 2022-05-25
Baseline population: Analysis was performed on all enrolled participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04330079: Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease
Official title: Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease (ENTRY Trial)
Sponsor: Asan Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Slow enrollment. (Difficulty in selecting subjects)
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-21
Primary completion date: 2021-04-08
Completion date: 2021-04-08
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04467346: Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules
Official title: Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules
Sponsor: Orphelia Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-25
Primary completion date: 2021-12-17
Completion date: 2021-12-17
Plan to share individual participant data: NO
Clinical trial NCT04047771: A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis
Official title: A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of SCB-313, Recombinant Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Trimer Fusion Protein, for the Treatment of Subjects With Peritoneal Carcinomatosis
Sponsor: Sichuan Clover Biopharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: terminated
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-10
Primary completion date: 2022-05-05
Completion date: 2022-05-05
Clinical trial NCT03559192: A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
Official title: A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive Disorder
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 181.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-16
Primary completion date: 2020-05-06
Completion date: 2020-05-06